Mechanisms of Semaglutide Therapy in Heart Failure Patients

Launched by UNIVERSITY MEDICAL CENTRE LJUBLJANA · Aug 5, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how semaglutide, a medication usually used to help manage diabetes, can benefit patients with heart failure and obesity. Researchers want to understand the specific ways semaglutide works in improving heart health and reducing hospital visits for heart failure in patients who also have obesity. The trial is currently looking for participants aged between 20 and 80 who have heart failure and a body mass index (BMI) of 27 or higher.

To be eligible, participants need to have stable heart failure treatments for at least three months and specific blood test results indicating heart strain. However, people with diabetes, certain types of cancer, severe liver or kidney issues, or those who have recently lost significant weight are not eligible to join the study. Participants can expect to receive careful monitoring and support throughout the trial, contributing to important research that could help improve treatment options for heart failure patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 20-80 years
• • Presence of heart failure
• • Body-mass index 27 kg/m2 or greater
• • Stable optimally tolerated dosages of heart failure therapies for 3 months
• • N-terminal pro B-type natriuretic peptide levels \>350 pg/mL
• Exclusion Criteria:
• • Presence of type 1 or type 2 diabetes or glycated haemoglobin higher than 6.5%
• • Pregnancy or potential to become pregnant
• • Cancer
• • Liver dysfunction (aspartate aminotransferase and/or alanine aminotransferase \> 3 times upper limits of normal or total bilirubin greater than 1.5 times upper limits of normal)
• • Renal dysfunction (estimated glomerular filtration rate less than 25 mL/min/1.73 m2)
• • Hospitalization in the past 3 months for reasons other than heart failure
• • New York Heart Association (NYHA) functional class I or functional class IV symptoms.
• • Prior or planned bariatric surgery
• • Self-reported change in body weight \>11 lbs (5 kg) within 3 months before enrollment
• • Acute or chronic infection